(RXDX)

業務介紹

普羅米修斯生物科學公司是一家生物製藥公司,從事發現、開發和商業化用於治療炎症性腸病(IBD)的創新療法和伴隨診斷產品。其主要產品包括PRA023,這是一種人源化IgG1單克隆抗體(mAb),正處於II期臨床試驗階段,用於治療潰瘍性結腸炎和克羅恩病,以及系統性硬化症相關的間質性肺病。該公司還開發了PR600(一種抗腫瘤壞死因子mAb,用於IBD)、PR300(一種G蛋白偶聯受體調節劑小分子,用於IBD)、PR1100(一種抗細胞因子受體mAb,用於IBD和其他免疫介導性疾病)、PR1800(一種抗趨化因子mAb,用於IBD)和PR2100(一種抗炎細胞因子mAb,用於IBD)。該公司與武田藥品工業株式會社有診斷開發和合作協議,與Dr. Falk Pharma GmbH有聯合開發和製造協議,與Cedars-Sinai Medical Center有許可協議,並與Millennium Pharmaceuticals, Inc.有戰略合作關係。該公司原名為Precision IBD, Inc.,於2019年10月更名為普羅米修斯生物科學公司。該公司成立於2016年,總部位於加利福尼亞州聖地亞哥。



Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

公司網址

https://www.prometheusbiosciences.com